Trending

Imfinzi

AZ withdraws Imfinzi in US bladder cancer use after trial failure

AZ withdraws Imfinzi in US bladder cancer use after trial failure

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer

X

AZ withdraws Imfinzi in US bladder cancer use after trial failure

https://pharmaphorum.com/news/az-withdraws-imfinzi-in-us-bladder-cancer-use-after-trial-setback/

AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancer

AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancer

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi

X

AZ nabs a positive study for Imfinzi plus tremelimumab in liver cancer

https://pharmaphorum.com/news/astrazeneca-imfinzi-tremelimumab-liver-cancer-asco-2020/

FDA approves AZ Imfinzi in new lung cancer use

FDA approves AZ Imfinzi in new lung cancer use

AstraZeneca has reported a double win after the FDA approved its Imfinzi for a form of lung cancer,

X

FDA approves AZ Imfinzi in new lung cancer use

https://pharmaphorum.com/news/fda-approves-az-imfinzi-in-new-lung-cancer-use/

AZ’s immunotherapy combo fails in phase 3 lung cancer trial

AZ’s immunotherapy combo fails in phase 3 lung cancer trial

AstraZeneca’s Imfinzi plus standard chemo improves overall survival in untreated extensive-stage small cell lung cancer – but a

X

AZ’s immunotherapy combo fails in phase 3 lung cancer trial

https://pharmaphorum.com/news/azs-immunotherapy-combo-fails-in-phase-3-lung-cancer-trial/

Finally, AZ claims a win with Imfinzi/tremelimumab cancer combo

Finally, AZ claims a win with Imfinzi/tremelimumab cancer combo

AstraZeneca’s development of checkpoint inhibitor combination Imfinzi and tremelimumab has chalked up serial trial failures in the last

X

Finally, AZ claims a win with Imfinzi/tremelimumab cancer combo

https://pharmaphorum.com/news/finally-az-claims-a-win-with-imfinzi-tremelimumab-cancer-combo/

AZ’s new cancer drugs drive another stellar quarter

AZ’s new cancer drugs drive another stellar quarter

AstraZeneca has raised its sales guidance of the year once again as its trio of new cancer drugs

X

AZ’s new cancer drugs drive another stellar quarter

https://pharmaphorum.com/news/azs-new-cancer-drugs-drive-another-stellar-quarter/

AstraZeneca cancer drugs approved in Japan

AstraZeneca cancer drugs approved in Japan

AstraZeneca secured a fast approval of lung and breast cancer drugs with usually sluggish Japanese regulators, just months

X

AstraZeneca cancer drugs approved in Japan

https://pharmaphorum.com/r-d/astrazenecas-cancer-drugs-approved-japan/

Groundbreaking lung cancer approval a big boost for AZ’s Imfinzi

Groundbreaking lung cancer approval a big boost for AZ’s Imfinzi

AstraZeneca’s immunotherapy Imfinzi has gained US approval in an important new earlier treatment setting for lung cancer patients.

X

Groundbreaking lung cancer approval a big boost for AZ’s Imfinzi

https://pharmaphorum.com/news/groundbreaking-lung-cancer-approval-big-boost-azs-imfinzi/

AstraZeneca spies an upturn at last in 2018

AstraZeneca spies an upturn at last in 2018

AstraZeneca (AZ) will see growth in its revenues once again in 2018, after several years of decline caused by blockbuster expiries.

X

AstraZeneca spies an upturn at last in 2018

https://pharmaphorum.com/news/astrazeneca-az-spies-upturn-last-2018/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com